Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025BiomedicinesOpen Access

Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlessio MazzieriLMLivia M. R. Marcon

Discussion

Loading...

Member takes

Overview

Narrative review demonstrates that SGLT2 inhibitors improve renal function in chronic kidney disease, suggesting a pivotal treatment role beyond glucose lowering.

Key Points

  • SGLT2 inhibitors significantly reduce the risk of cardiorenal events through their nephroprotective mechanisms.
  • The key metabolic effects include reducing uric acid and blood sugar levels, enhancing the glomerular filtration rate.
  • Wide-ranging benefits also include anti-inflammatory and antifibrotic effects that improve cardiovascular health.
  • SGLT2 inhibitors are a mainstay treatment in chronic kidney disease, even for patients without diabetes mellitus.

Cite This Study

Mazzieri et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477d646https://doi.org/10.3390/biomedicines13092123
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global burden of heart failure: a comprehensive and updated review of epidemiology2022 · 3,322 citations
  2. 2Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015 · 12,286 citations